Drug interaction assessment following concomitant administration of posaconazole and phenytoin in healthy men

References

• Wingard JR. Infections due to resistant Candida species in patients with cancer who are receiving chemotherapy. Clin Infect Dis 1994;19(Suppl 1):S49–53
   PubMed Web of Science ®Google Scholar
• Wingard JR, Leather HL. Empiric antifungal therapy for the neutropenic patient. Oncology (Huntingt) 2001;15:351–63
   PubMed Web of Science ®Google Scholar
• Jahagirdar BN, Morrison VA. Emerging fungal pathogens in patients with hematologic malignancies and marrow/stem-cell transplant recipients. Semin Respir Infect 2002;17:113–20
   PubMedGoogle Scholar
• Paya CV. Fungal infections in solid-organ transplantation. Clin Infect Dis 1993;16:677–88
   PubMed Web of Science ®Google Scholar
• Marty F, Mylonakis E. Antifungal use in HIV infection. Expert Opin Pharmacother 2002;3:91–102
   PubMedGoogle Scholar
• Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002;34:909–17
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Jones RN, Messer SA, et al. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and anti-fungal susceptibility in the SCOPE program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic Importance. Diagn Microbiol Infect Dis 1998;30:121–9
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Hollis RJ, et al. In vitro activities of posaconazole (SCH 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans. Antimicrob Agents Chemother 2001;45:2862–4
   PubMed Web of Science ®Google Scholar
• Barchiesi F, Schimizzi AM, Caselli F, et al. Activity of the new antifungal triazole, posaconazole, against Cryptococcus neoformans. J Antimicrob Chemother 2001;48:769–73
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Hollis RJ, et al. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002;46: 1032–7
   Google Scholar
• Sabatelli F, Patel R, Mann PA, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006;50:2009–15
   PubMed Web of Science ®Google Scholar
• Sun QN, Fothergill AW, McCarthy DI, et al. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of Zygomycetes. Antimicrob Agents Chemother 2002;46:1581–2
   PubMed Web of Science ®Google Scholar
• Meletiadis J, Meis JF, Mouton JW, et al. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother 2002;46:62–8
   PubMed Web of Science ®Google Scholar
• Raad II, Graybill JR, Bustamante AB, et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 2006;42:1726–34
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Cornely OA, Burchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006;50:658–66
   PubMed Web of Science ®Google Scholar
• van Burik JA, Hare RS, Solomon HF, et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006;42:e61–5
   PubMed Web of Science ®Google Scholar
• Courtney R, Pai S, Laughlin M, et al. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003;47:2788–95
   PubMed Web of Science ®Google Scholar
• Krishna G, Sansone-Parsons A. Pharmacokinetics of posaconazole in healthy volunteers: a meta-analysis of five phase 1 studies. Presented at: 41st American Society of Health-System Pharmacists Midyear Clinical Meeting and Exhibition December 3–7, 2006 Anaheim, Calif 2006
   Google Scholar
• Courtney R, Wexler D, Radwanski E, et al. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2003;57:218–22
   Web of Science ®Google Scholar
• Sansone-Parsons A, Krishna G, Calzetta A, et al. Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob Agents Chemother 2006;50:1881–3
   Google Scholar
• De Beule K, Van Gestel J. Pharmacology of itraconazole. Drugs 2001;61(Suppl 1):27–37
   PubMedGoogle Scholar
• Hoffman HL, Rathbun RC. Review of the safety and efficacy of voriconazole. Expert Opin Investig Drugs 2002;11:409–29
   PubMed Web of Science ®Google Scholar
• Krieter P, Flannery B, Musick T, et al. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 2004;48:3543–51
   PubMed Web of Science ®Google Scholar
• Wexler D, Courtney R, Richards W, et al. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, twoway crossover study. Eur J Pharm Sci 2004;21:645–53
   PubMed Web of Science ®Google Scholar
• Gubbins PO, Amsden JR. Drug-drug interactions of antifungal agents and implications for patient care. Exp Opin Pharmacother 2005;6:2231–43
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, Von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000;38:111–80
   PubMed Web of Science ®Google Scholar
• Albengres E, Le Louet H, Tillement JP. Systemic antifungal agents: drug interactions of clinical significance. Drug Saf 1998;18:83–97
   PubMed Web of Science ®Google Scholar
• Mitchell AS, Holland JT. Fluconazole and phenytoin: a predictable interaction [letter]. BMJ 1989;298:1315
   PubMed Web of Science ®Google Scholar
• Blum RA, Wilton JH, Hilligoss DM, et al. Effect of fluconazole on the disposition of phenytoin. Clin Pharmacol Ther 1991;49:420–5
   PubMed Web of Science ®Google Scholar
• Ducharme MP, Slaughter RL, Warbasse LH, et al. Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. Clin Pharmacol Ther 1995;58:617–24
   PubMed Web of Science ®Google Scholar
• Purkins L, Wood N, Ghahramani P, et al. Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. Br J Clin Pharmacol 2003;56 Suppl 1:37–44
   PubMed Web of Science ®Google Scholar
• Gibaldi M, Perrier D. Pharmacokinetics, 2nd edn. New York: Marcel Dekker, 1982
   Google Scholar
• Ghosal A, Hapangama N, Yuan Y, et al. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil). Drug Metab Dispos 2004;32:267–71
   PubMed Web of Science ®Google Scholar
• Anderson GD. Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs. Neurology 2004;63 (Suppl 4):S3–8
   PubMedGoogle Scholar
• Tucker RM, Denning DW, Hanson LH, et al. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis 1992;14:165–74
   PubMed Web of Science ®Google Scholar
• Anderson GD. A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother 1998;32:554–63
   PubMed Web of Science ®Google Scholar
• Crowley JJ, Cusack BJ, Jue SG, et al. Aging and drug interactions. II. Effect of phenytoin and smoking on the oxidation of theophylline and cortisol in healthy men. J Pharmacol Exp Ther 1988;245:513–23
   Google Scholar
• Fleishaker JC, Pearson LK, Peters GR. Phenytoin causes a rapid increase in 6 beta-hydroxycortisol urinary excretion in humans - a putative measure of CYP3A induction. J Pharm Sci 1995;84: 292–4
   Google Scholar
• Tomlinson B, Young RP, Ng MC, et al. Selective liver enzyme induction by carbamazepine and phenytoin in Chinese epileptics. Eur J Clin Pharmacol 1996;50:411–15
   PubMed Web of Science ®Google Scholar